Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Combined Serology and Genotyping Reduces False Positive Diagnosis of Celiac Disease

By LabMedica International staff writers
Posted on 09 Sep 2013
A new diagnostic approach for detection of celiac disease (CD) that combines genomic assessment and serology revealed that this immune disorder is far more common in the Australian population than previously thought but was often diagnosed incorrectly.

Investigators at the Walter and Eliza Hall Institute (Victoria, Australia) and their colleagues combined traditional antibody testing for CD (measuring the immune response to gluten) with an assessment of specific genetic risk markers.

They evaluated serum samples from 356 patients with biopsy-confirmed CD, and from two age-stratified, randomly selected community cohorts of 1,390 women and 1,158 men. More...
The samples were tested for antigluten antibodies by standard serological techniques and (HLA)-DQ genotyping was performed using Taqman SNP genotyping methods (Applied Biosystems, Foster City, CA, USA) following the manufacturer’s protocols.

Results revealed that celiac disease potentially affected at least one in 60 Australian women and one in 80 men. Previous estimates had suggested that the number of Australians with celiac disease was no more than 1%. Furthermore, serogenetic data indicated that testing screen positives for HLA-DQ, or carrying out HLA-DQ and further serology, could have reduced unnecessary gastroscopies due to false-positive serology by at least 40% and by over 70%, respectively.

“Currently, bowel biopsies are recommended for anybody with positive antibody tests,” said contributing author Dr. Jason Tye-Din, a gastroenterologist at the Walter and Eliza Hall Institute. “In this study, the inclusion of a simple genetic test helped identify a substantial number of people whose antibody tests were falsely positive and who did not actually require a bowel biopsy to test for the possibility of celiac disease.”

“It is concerning that a significant number of people in the community with celiac disease have not been diagnosed,” said Dr. Tye-Din. “Accurate and timely diagnosis is important for the health of patients with celiac disease. Making a diagnosis based on a blood test alone or commencing a gluten-free diet without a confirmatory bowel biopsy is inappropriate and can impose an unnecessary and lifelong treatment. Although small bowel biopsy is needed to confirm celiac disease, it is costly and invasive. Reducing unnecessary procedures is better for patients, eliminating an invasive test, and better for the economy by reducing healthcare costs. This study provides a strategy to improve the diagnosis of celiac disease in the community by combining the benefits of antibody and genetic testing.”

Related Links:
Applied Biosystems
Walter and Eliza Hall Institute



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.